Literature DB >> 21702980

TFRC and ACTB as the best reference genes to quantify Urokinase Plasminogen Activator in breast cancer.

Keivan Majidzadeh-A1, Rezvan Esmaeili, Nasrin Abdoli.   

Abstract

BACKGROUND: Biomedical researchers have long looked for ways to diagnose and treat cancer patients at the early stages through biomarkers. Although conventional techniques are routinely applied in the detection of biomarkers, attitudes towards using Real-Time PCR techniques in detection of many biomarkers are increasing. Normalization of quantitative Real-Time PCR is necessary to validate non-biological alteration occurring during the steps of RNA quantification. Selection of variably expressed housekeeping genes (HKs) will affect the validity of the data. The aim of the present study was to identify uniformly expressed housekeeping genes in order to use in the breast cancer gene expression studies. Urokinase Plasminogen Activator was used as a gene of interest.
FINDINGS: The expression of six HKs (TFRC, GUSB, GAPDH, ACTB, HPRT1 and RPLP0) was investigated using geNorm and NormFinder softwares in forty breast tumor, four normal and eight adjacent tissues. RPLP0 and GAPDH revealed maximum M value, while TFRC demonstrated lowest M value.
CONCLUSIONS: In the present study the most and the least stable genes were TFRC and RPLP0 respectively. TFRC and ACTB were verified as the best combination of two genes for breast cancer quantification. The result of this study shows that in each gene expression analysis HKs selection should be done based on experiment conditions.

Entities:  

Year:  2011        PMID: 21702980      PMCID: PMC3141519          DOI: 10.1186/1756-0500-4-215

Source DB:  PubMed          Journal:  BMC Res Notes        ISSN: 1756-0500


Introduction

Worldwide, breast cancer is the most frequent cancer among women. It affects more than one million women globally, accounting for more than 400,000 deaths annually [1]. In Iran as an Asian country, among women over 30, the incidence and prevalence rate of breast cancer is 22 and 120 per 100,000, respectively [2]. For a long time, biomedical scientists have been interested in finding ways to diagnose and to treat cancer patients at early stages. Research aimed at developing robust biomarkers and reliable assays, has made progress in the detection, diagnosis, and treatment of breast cancer. Only a limited number of biomarkers for breast cancer are currently available which assist in making breast cancer management decisions. Oncotype DX; a diagnostic panel commercially available; is indicated for specified breast cancer patients that predicts the risk of a patient experiencing a recurrence [3]. Estrogen receptor (ER), progesterone receptor (PR) and Her2/neu status are routinely measured to decide about hormone and targeted therapy. In addition, recommendations concerning the role of urokinase plasminogen activator (uPA) in detecting the invasive nature of the tumors have been recently added to the clinical guidelines [4]. Current routine assays for quantifying biomarkers, such as immunohistochemistry (IHC) and Enzyme-linked immunosorbent assay (ELISA) are approved and valid, and are reproducible between different laboratories [5-8]. However, unquantifiable results and long procedure time are among the drawbacks of these methods which have persuaded researchers to seek alternative modern molecular based techniques such as quantitative Real-Time PCR (Q-RT-PCR) [9,10]. Q-RT-PCR is highly cost-effective, very fast, and one of the most sensitive and specific quantification methods for gene expression analysis [11,12]. To be approved as a routine alternative method for conventional techniques; however, a number of validations are necessary for Q-RT-PCR including HK validation. Differences occurring during the steps of RNA quantification would be normalized by endogenous controls (ECs). There are large scale gene expression profiling studies in which hundreds of HKs were identified [13-15]. During the years of using Q-RT-PCR, based on this belief that housekeeping genes have uniform expression regardless of biological conditions, they have been applied for quantification. Several studies have revealed significant alterations in the expression of a number of ECs affecting validity of expression analysis [16-20]. Since reliability of ECs affects the accuracy of the normalized data, reference gene selection plays an important role in this matter. HK validations have been performed for a number of genes but, to the best of our knowledge, no report has been found for uPA in breast cancer. The uPA is involved in various biological processes. Along with some other genes, elevated expression of uPA in plasminogen activation system takes part in tumor cell invasion and metastatic process. High level expression of this marker represents an unfavorable prognostic factor for metastasis in breast cancer [6,21]. The aim of the present study was to validate reference genes in order to select the most appropriate ECs for uPA quantification in breast cancer tissues.

Methods

Breast tumor tissues (n = 40), normal tissues (n = 4) and normal adjacent tissues (n = 8), were taken from Iranian Center for Breast Cancer Biobank (ICBC-BB). According to the protocols followed by ICBC-BB, immediately after excisional biopsy or surgery, sample tissues were snap-frozen in liquid nitrogen and stored at -70°C. ICBC-BB is obliged to ethical guidelines and recommendations for biobanks on the storage and use of human biological samples. Clinical and histopathological features of patients are summarized in table 1.
Table 1

Clinical and histological data of malignant and normal adjacent breast tissues.

Tissue typeAgeSize (mm)Tumor stagegradeHistological typeMenoposal statusERPRHer2/neuP53
Adjacent50
Adjacent38---+
Malignant3818IIAIIIIDCpre++-
Malignant3820IIIIDCpre3+3+2+
Malignant5835IIIAIIIDCpost---+
Malignant8010IIDCpost++-
Malignant5430IIBIIIDCpost
Adjacent++3++
Malignant4025IIBIIIDCpre++-+
Malignant3520IIIIDCpost
Adjacent
Malignant++-+
Malignant5221IIAIIIDCpost++-+
MalignantIIIIDC+--+
Malignant8250IIBIIIIDCpost
Adjacent43++--
Malignant5050IIAIIIDCpre3+3+-
Malignant4420IIIAIIIIDCpre++-
Malignant5120IIAIIIDCpost
Malignant++--
Malignant3760IIIBIIIDCpost
Malignant45IDCpre++-
Malignant4015IBIIIDCpre---+
Malignant4220IVIIIIDCpre++-+
Malignant5221IIAIIIDCpost++--
Malignant508IIAIIIDCpost++-
Malignant5430IIAIIIDCpost----
Malignant45IVIDCpre
Adjacent45
Adjacent40
Adjacent52
Adjacent42----
Malignant53IDC+DCISpre++3+-
Malignant3410IIBIIIDC+DCISpre---+
Malignant5638IIBIIIDCpost++-
Malignant7120IVIIIDCpost----
Malignant3430IIAIIIDCpre++3+
Malignant37IIIDCpre---
Malignant4830IIBILCpre++-+
Malignant4318Ipre-+-
Malignant4520IIIIILCpre--3++
Malignant39100IIIAIIIDCpre
Malignant3460IIIIDCpre
Malignant
Normal25
Normal38
Normal32
Normal++--
Malignant5015IBIIDCpre--3++
Malignant3210IVIIIDCpre+--
Malignant6030IVIIIDCpost++--
Malignant4150IVIIDCpre

Stage grouping are based on American Joint Committee on Cancer (AJCC). Estrogen receptor(ER), progesterone receptor (PR), Her2/neu and P53 status are based on IHC results. Invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC)

Clinical and histological data of malignant and normal adjacent breast tissues. Stage grouping are based on American Joint Committee on Cancer (AJCC). Estrogen receptor(ER), progesterone receptor (PR), Her2/neu and P53 status are based on IHC results. Invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC) Tissues (8-20 mg) were excised on dry ice and homogenized in 1 ml of RnxPlus (Cinnagen, Iran) to extract RNA according to manufacturer directions. Extracted RNAs were quantified by spectrophotometer (Hitachi, U-0080D, Japan) and the Absorbance ratio at 260/280 and 260/230 were measured to control the purity of the RNA. The integrity of RNA was confirmed by checking ribosomal RNA with electrophoresis on a 1% agarose gel. Then, 3.6 μg of RNA was treated with 18 unit of RNase-free DNase (Fermentas AB, Vilnius, Lithuania), 20 units of RNase inhibitor (Fermentas AB, Vilnius, Lithuania) and 2.4 μl of 25 mM MgCl2. The total volume of reaction was 30 μl. The reaction was incubated in 37°C for 15 min and then 90°C for 5 min to inactivate the DNase.1 μg of total RNA was transcribed to cDNA using Precision™reverse transcription kit (PrimerDesign Ltd, UK). Six common housekeeping genes in breast cancer; TFRC, GUSB, GAPDH, ACTB, HPRT1 and RPLP0; were selected and their stability were examined in order to normalize expression of uPA. All primers and probes were designed using Gene Runner v.3.05 and confirmed with primer express 3.0 (Table 2). Amplification efficiency for each primer was approximated using 10 fold cDNA serial dilutions and calculated using 7500 software system ver. 2.0. The serial dilutions were performed using pooled cDNA from 15 tumor cDNAs with equal proportion. CDNA synthesis was done as mentioned above.
Table 2

Primer probe sets.

TargetAccession No.SequenceMelting TMefficiency
GAPDHNM_001002F GAAGGTGAAGGTCGGAGTC61.394
R GGGTGGAATCATATTGGAACA63.2
P ATTTGGTCGTATTGGGCGCCTGGT74.9
TFRCNM_003234F ACCGGCACCATCAAGCT64.594
R TGATCACGCCAGACTTTGC65.2
P TGAAAATTCATATGTCCCTCGTGAGGCT72.1
RPLP0NM_001002F CGGACGAGGATATGGGATTTG67.289
R AGAAGTAAGCCTTTATTTCCTTGTTT64.7
P TCACCAAAAAGCAACCAACTTAGCCAGT72
GUSBNM_000181F GCGTTCCTTTTGCGAGGAGA68.674
R GGTGGTATCAGTCTTGCTCAA64.7
P ACCAGGTATCCCCACTCAGTAGCCAAG72
HPRT1NM_000194F TGGACTAATTATGGACAGGACTGAA64.4103
R GTAATCCAGCAGGTCAGCAA62.8
P CTTGCTCGAGATGTGATGAAGGAGATGG73.7
UPANM_002658F AGGGCAGCACTGTGAAATAGATAAGT65.797
R CATGGTACGTTTGCTGAAGGA64.8
P TTACCGAGGAAAGGCCAGCACTGACA75.3
ACTBNM_001101F CAGCAGATGTGGATCAGCAAG65.995
R GCATTTGCGGTGGACGAT67.1
P AGGAGTATGACGAGTCCGGCCCC73.8

Probes were labeled with 5' FAM and 3' TAMRA.

Primer probe sets. Probes were labeled with 5' FAM and 3' TAMRA.

Quantitative Real-Time PCR

Q-RT-PCR was carried out in triplicate format within the same 96-well plate for each sample using precision™ 2 × qPCR Mastermix (PrimerDesign Ltd, UK) in 20 μl reactions. Primer and probe concentrations were 0.5 μM and 0.3 μM, respectively. Fluorescent detection was performed using Applied Biosystems 7500 System. Data were analyzed using SDS software, vers.2.0 (Applied Biosystems).

Data analysis and endogenous control stability

Raw data of Q-RT-PCR was analyzed using SDS software, vers.2.0 (Applied Biosystems). Samples with standard deviation greater than 0.5 from the mean threshold cycle (CT) of the replicates were excluded. In order to find the most stable housekeeping gene, the data were transformed to linear scale values with Excel. Analyses were done by pairwise comparison approach applying geNorm software[19] as well as combined estimation of the intra and inter group validation using NormFinder software[22]. UPA expression measurement was performed using ΔΔCT method with RPLP0 or combination of ACTB and TFRC as endogenous control. Comparison between the mean of each group was done using paired sample t-test (SPSS v.13) with 95% confidence interval.

Results

Threshold cycle (CT) values of endogenous controls and uPA are shown in table 3.
Table 3

threshold cycle (CT) values of endogenous controls and uPA.

GeneCT RangeCT MinCT MaxMean ± s.e.m
RPLP022.6819.5242.229.69 ± 0.81
GUSB8.6127.5936.231.99 ± 0.33
TFRC15.6425.2740.9231.7 ± 0.5
HPRT114.2526.4240.6732.61 ± 0.43
ACTB14.0516.9330.9825.1 ± 0.5
GAPDH19.222.6941.8929.3 ± 0.5
UPA10.6528.1338.7831 ± 0.38
threshold cycle (CT) values of endogenous controls and uPA. The range of threshold cycles (CT Range) was between 8.61 and 22.68 among endogenous candidate genes with a mean value ranging from 25.1 (± 0.5 s.e.m) for ACTB to 32.61(± 0.43 s.e.m) for GUSB. The maximum and minimum expression ranges were 22.68 cycles for GUSB and 8.61 cycles for ACTB respectively (Table3). Data were analyzed using geNorm and NormFinder software programs. GeNorm calculates pairwise variation to find the most stable expressed ECs, and thereby computing the average expression stability value (M) and plotting it for each gene. In this study, RPLP0 and GAPDH revealed maximum M while TFRC demonstrated lowest M value (Figure 1). The most stable expressed gene was TFRC. The GeNorm software also calculates normalization factor (V); the point at which addition of extra endogenous control is unnecessary; to find the optimal number of required ECs. According to GeNorm software manual, recommended V-value cut-off was 0.15 but it was also mentioned that proposed value must not be taken as a too strict cut-off. In this study the V-values of using 3 and 4 ECs were calculated as 0.5 and 0.4, respectively (Figure 2).
Figure 1

GeNorm analysis of candidate genes: genes with low Average expression stability M which are plotted in the right side of x-axis indicate greater stability.

Figure 2

Determination of the optimal number of ECs for normalization: Inclusion of additional reference gene is not required for pairwise variation values (V value) below 0.15.

GeNorm analysis of candidate genes: genes with low Average expression stability M which are plotted in the right side of x-axis indicate greater stability. Determination of the optimal number of ECs for normalization: Inclusion of additional reference gene is not required for pairwise variation values (V value) below 0.15. NormFinder software; an algorithm for identifying the optimal normalization gene among a set of candidates; was used to rank the set of candidate normalization genes according to their expression stability in a given sample set. In this study, NormFinder determined TFRC as the most stable EC Followed by GUSB and ACTB genes (Table 4).
Table 4

Stability values of reference genes using geNorm and NormFinder programs

geNormNormFinder
RankGene nameStability (M value)Gene nameStability

1TFRC2.846TFRC0.796
2GUSB2.902GUSB1.007
3ACTB2.984ACTB1.130
4HPRT13.298HPRT11.799
5GAPDH3.538GAPDH1.984
6RPLP04.737RPLP02.966

Genes with lower number are more stable.

Stability values of reference genes using geNorm and NormFinder programs Genes with lower number are more stable. Statistical comparison of "uPA expression results normalized with RPLP0" in one group and "the combination of TFRC and ACTB" in another group showed significant difference in uPA expression amounts (p-value < 0.05).

Discussion

During recent years traditional attitudes towards therapeutic care has been replaced with individualized medicine especially in the cancer field. It is recommended to assess approved markers in order to select the best therapeutic models instead of blind administration of similar regimens for all patients. Among current systems, gene expression profiling plays a major role in tailoring treatment to the individual strategy. Despite the accuracy of routinely used approved methods for detection of biomarkers such as IHC for measurement of Her2 and ER biomarkers and ELISA for uPA, there are still disadvantages. For instance, ELISA requires a substantial amount of tissue and small tissues of early stage cancer would be difficult to be analyzed [4]. Several studies using various types of design have been conducted to determine whether novel molecular techniques like Q-RT-PCR may be added to routine approved methods for detection and quantification of biomarkers [23-31]. To our knowledge this is the first study on determining reference gene in breast cancer for quantification of uPA. We found that TFRC and ACTB is the best combination of two genes with the greatest expression stability. GeNorm and NormFinder without sub grouping had a similar performance in detecting the most and the least stable genes. TFRC and RPLP0 were the most and the least satiable genes. GAPDH and ACTB were among the least and the most stable genes which a in concordance with other breast cancer studies [17,32-35]. Both softwares recognized the same order of stability for all of the genes (Table4). Other Studies suggest different genes. Mc Neill et al in a study for ER quantification, suggested MRPL19 and PPIA as the most stable and RPLP0 as the least stable genes, while in the study by Lyng et al TBP, RPLP0 and PUM1 were recommend for normalization [36]. Moreover, 18S rRNA and HPRT1 have been suggested for breast cancer normalization in quantification of Her2/neu [18,34]. Housekeeping selection is a critical step in Q-RT-PCR analysis. The idea that housekeeping genes (ECs) pose constant expression in different cells may influence their selection in various studies. In the study by Mc Neill et al the data of housekeeping gene selection in colorectal and ovarian cancer was used to decide about selection of an EC for breast cancer [17]. It should be noted that instability of one housekeeping gene in specific cancer does not mean instability in other cancers. The important key is that housekeeping gene expression patterns are influenced by cancer mechanism and EC selections should be made for each cancer separately [37,38]. Housekeeping generalization may result in inappropriate set of ECs because some genes may be included or excluded erroneously based on other cancer evidences. It is also noteworthy that various experiment conditions in the studies may change the expression of the housekeeping genes. As a result, dissimilar genes may be found as the best reference for normalization in different studies with different conditions.

Conclusions

To conclude, it appears that identifying a universal housekeeping for gene expression analysis is far from reality. Thus, stability of controls should be checked based on the tissue type and experiment design. On the basis of our findings, we suggest that TFRC is the most stable EC, ACTB and TFRC is the best combination of two reference genes to quantify uPA, and that using RPLP0 and GAPDH are not recommendable for breast cancer. The authors also suggest testing with large sample size and more candidate reference gene to find more stable ECs.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

KM conceived and designed the project and critically reviewed data analysis and manuscript. RE designed the experiment, was responsible for experiments set up, data analysis and writing the manuscript. NA was responsible for collecting samples and performing the experiments. All authors read and approved the final manuscript.
  37 in total

1.  Human housekeeping genes are compact.

Authors:  Eli Eisenberg; Erez Y Levanon
Journal:  Trends Genet       Date:  2003-07       Impact factor: 11.639

2.  Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.

Authors:  Julia C Biermann; Leon Holzscheiter; Matthias Kotzsch; Thomas Luther; Marion Kiechle-Bahat; Fred C G J Sweep; Paul N Span; Manfred Schmitt; Viktor Magdolen
Journal:  Int J Mol Med       Date:  2008-02       Impact factor: 4.101

3.  Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.

Authors:  Remedios Castelló; Amparo Estellés; Carlos Vázquez; Cristina Falcó; Francisco España; Sergio M Almenar; Carlos Fuster; Justo Aznar
Journal:  Clin Chem       Date:  2002-08       Impact factor: 8.327

4.  Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens.

Authors:  P de Cremoux; C Tran-Perennou; B L Brockdorff; E Boudou; N Brünner; H Magdelénat; A E Lykkesfeldt
Journal:  Endocr Relat Cancer       Date:  2003-09       Impact factor: 5.678

5.  Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes.

Authors:  Jacques B de Kok; Rian W Roelofs; Belinda A Giesendorf; Jeroen L Pennings; Erwin T Waas; Ton Feuth; Dorine W Swinkels; Paul N Span
Journal:  Lab Invest       Date:  2005-01       Impact factor: 5.662

6.  Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer.

Authors:  Andreea Nistor; Peter H Watson; Norman Pettigrew; Karim Tabiti; Angelika Dawson; Yvonne Myal
Journal:  BMC Clin Pathol       Date:  2006-01-18

7.  Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of breast cancer.

Authors:  Roisin E McNeill; Nicola Miller; Michael J Kerin
Journal:  BMC Mol Biol       Date:  2007-11-27       Impact factor: 2.946

8.  Identification of genes for normalization of real-time RT-PCR data in breast carcinomas.

Authors:  Maria B Lyng; Anne-Vibeke Laenkholm; Niels Pallisgaard; Henrik J Ditzel
Journal:  BMC Cancer       Date:  2008-01-22       Impact factor: 4.430

9.  De-regulation of common housekeeping genes in hepatocellular carcinoma.

Authors:  Samuel Waxman; Elisa Wurmbach
Journal:  BMC Genomics       Date:  2007-07-18       Impact factor: 3.969

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  20 in total

1.  High expression of CEACAM19, a new member of carcinoembryonic antigen gene family, in patients with breast cancer.

Authors:  Mehrdad Asghari Estiar; Rezvan Esmaeili; Ali-Akbar Zare; Leila Farahmand; Hassan Fazilaty; Ali Zekri; Narges Jafarbeik-Iravani; Keivan Majidzadeh-A
Journal:  Clin Exp Med       Date:  2016-12-01       Impact factor: 3.984

2.  Identification of stable reference genes for gene expression analysis of three-dimensional cultivated human bone marrow-derived mesenchymal stromal cells for bone tissue engineering.

Authors:  Juliane Rauh; Angela Jacobi; Maik Stiehler
Journal:  Tissue Eng Part C Methods       Date:  2014-08-11       Impact factor: 3.056

3.  Selecting housekeeping genes as references for the normalization of quantitative PCR data in breast cancer.

Authors:  Y Kılıç; A Ç Çelebiler; M Sakızlı
Journal:  Clin Transl Oncol       Date:  2013-05-30       Impact factor: 3.405

4.  MicroRNAs and their target mRNAs as potential biomarkers among smokers and non-smokers with lung adenocarcinoma.

Authors:  Sumaria Malik; Rehan Zafar Paracha; Maryam Khalid; Maryum Nisar; Amnah Siddiqa; Zamir Hussain; Raheel Nawaz; Amjad Ali; Jamil Ahmad
Journal:  IET Syst Biol       Date:  2019-04       Impact factor: 1.615

Review 5.  Quantification of HER family receptors in breast cancer.

Authors:  Paolo Nuciforo; Nina Radosevic-Robin; Tony Ng; Maurizio Scaltriti
Journal:  Breast Cancer Res       Date:  2015-04-09       Impact factor: 6.466

6.  Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.

Authors:  Brett Wallden; James Storhoff; Torsten Nielsen; Naeem Dowidar; Carl Schaper; Sean Ferree; Shuzhen Liu; Samuel Leung; Gary Geiss; Jacqueline Snider; Tammi Vickery; Sherri R Davies; Elaine R Mardis; Michael Gnant; Ivana Sestak; Matthew J Ellis; Charles M Perou; Philip S Bernard; Joel S Parker
Journal:  BMC Med Genomics       Date:  2015-08-22       Impact factor: 3.063

7.  Identification of valid reference genes for the normalization of RT-qPCR expression studies in human breast cancer cell lines treated with and without transient transfection.

Authors:  Lin-Lin Liu; Hui Zhao; Teng-Fei Ma; Fei Ge; Ce-Shi Chen; Ya-Ping Zhang
Journal:  PLoS One       Date:  2015-01-24       Impact factor: 3.240

8.  An unsupervised learning approach to find ovarian cancer genes through integration of biological data.

Authors:  Christopher Ma; Yixin Chen; Dawn Wilkins; Xiang Chen; Jinghui Zhang
Journal:  BMC Genomics       Date:  2015-08-17       Impact factor: 3.969

9.  Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens.

Authors:  Torsten Nielsen; Brett Wallden; Carl Schaper; Sean Ferree; Shuzhen Liu; Dongxia Gao; Garrett Barry; Naeem Dowidar; Malini Maysuria; James Storhoff
Journal:  BMC Cancer       Date:  2014-03-13       Impact factor: 4.430

10.  Reference genes for expression studies in hypoxia and hyperglycemia models in human umbilical vein endothelial cells.

Authors:  Sherin Bakhashab; Sahira Lary; Farid Ahmed; Hans-Juergen Schulten; Ayat Bashir; Fahad W Ahmed; Abdulrahman L Al-Malki; Hasan S Jamal; Mamdooh A Gari; Jolanta U Weaver
Journal:  G3 (Bethesda)       Date:  2014-09-05       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.